ArticleFrontiers in oncology2026
Development and validation of a nomogram based on tumor margin irregularity and alpha-fetoprotein for predicting microvascular invasion in hepatocellular carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and externally validate a preoperative nomogram based on tumor margin irregularity and alpha-fetoprotein (AFP) positivity for predicting microvascular invasion (MVI) in hepatocellular carcinoma (HCC). Methods: This retrospective multicenter study included a training cohort of 487 patients and an external validation cohort of 256 patients with pathologically confirmed HCC after liver resection. Demographic, clinical, tumor-related, serological, and preoperative computed tomography (CT) variables were compared by MVI status. Two blinded radiologists independently assessed qualitative CT features, and interobserver agreement was evaluated using Cohen's κ. Least Absolute Shrinkage and Selection Operator (LASSO) regression with 10-fold cross-validation was used for predictor selection, followed by multivariable logistic regression. Model performance was assessed by receiver operating characteristic (ROC) curves, area under the curve (AUC), DeLong tests, calibration, the Hosmer-Lemeshow test, and decision curve analysis (DCA). Tumor size-related sensitivity analyses were performed. Results: MVI was present in 187 of 487 patients in the training cohort and 95 of 256 patients in the validation cohort. LASSO selected AFP positivity, irregular tumor margins, capsular interruption, and intratumoral hyperplastic vessels. Multivariable analysis identified irregular tumor margins (adjusted odds ratio [OR] = 5.275, 95% confidence interval [CI]: 3.165-8.791, p < 0.001) and AFP positivity (adjusted OR = 3.297, 95% CI: 1.983-5.481, p < 0.001) as independent predictors. The final two-variable model achieved AUCs of 0.740 and 0.781 in the training and validation cohorts. Tumor size did not materially improve discrimination, and model performance was generally consistent across size categories. Calibration was acceptable, and DCA suggested exploratory clinical utility. Conclusion: The nomogram based on tumor margin irregularity and AFP positivity showed fair-to-acceptable discrimination and may support exploratory preoperative MVI risk stratification in surgically treated or resectable HCC patients with clinical characteristics similar to those in the study cohorts, pending prospective multicenter validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.